ATE305971T1 - Monoklonale antikörper und fv gegen das cd2 antigen - Google Patents
Monoklonale antikörper und fv gegen das cd2 antigenInfo
- Publication number
- ATE305971T1 ATE305971T1 AT94108104T AT94108104T ATE305971T1 AT E305971 T1 ATE305971 T1 AT E305971T1 AT 94108104 T AT94108104 T AT 94108104T AT 94108104 T AT94108104 T AT 94108104T AT E305971 T1 ATE305971 T1 AT E305971T1
- Authority
- AT
- Austria
- Prior art keywords
- sfv
- hiv
- monoclonal antibody
- cells
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/068,946 US5795572A (en) | 1993-05-25 | 1993-05-25 | Monoclonal antibodies and FV specific for CD2 antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE305971T1 true ATE305971T1 (de) | 2005-10-15 |
Family
ID=22085730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94108104T ATE305971T1 (de) | 1993-05-25 | 1994-05-25 | Monoklonale antikörper und fv gegen das cd2 antigen |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5795572A (de) |
| EP (1) | EP0626447B1 (de) |
| JP (1) | JP3863196B2 (de) |
| AT (1) | ATE305971T1 (de) |
| CA (1) | CA2124126C (de) |
| DE (1) | DE69434499T2 (de) |
| DK (1) | DK0626447T3 (de) |
| ES (1) | ES2249759T3 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| DE69927831T2 (de) * | 1998-08-31 | 2006-07-20 | Biogen, Inc., Cambridge | Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens |
| US7361338B2 (en) * | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| US6790631B1 (en) * | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| AU2008200400B2 (en) * | 2001-01-17 | 2012-06-07 | Aptevo Research And Development Llc | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101684158A (zh) | 2001-01-17 | 2010-03-31 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| WO2003009740A2 (en) | 2001-07-24 | 2003-02-06 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
| US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005077018A2 (en) * | 2004-02-06 | 2005-08-25 | Astellas Us Llc | Methods of treating skin disorders |
| KR20070011558A (ko) * | 2004-05-04 | 2007-01-24 | 제네상스 파머슈티컬스, 아이엔씨. | 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법 |
| CA2565259A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
| KR20070050934A (ko) * | 2004-08-30 | 2007-05-16 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Ｔ-세포 조절에 의한 ｈｉｖ 감염의 치료 방법 |
| EP2295080A3 (de) * | 2005-07-25 | 2011-06-22 | Emergent Product Development Seattle, LLC | B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| SMT201800284T1 (it) | 2011-06-10 | 2018-07-17 | Univ Oregon Health & Science | Glicoproteine cmv e vettori ricombinanti |
| EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
| EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
| EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
| US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US11820807B2 (en) * | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
| ES2983120T3 (es) * | 2015-06-12 | 2024-10-21 | Ubi Pharma Inc | Proteínas de fusión de inmunoglobulinas y usos de las mismas |
| DK3328881T3 (da) | 2015-09-08 | 2019-10-07 | Theripion Inc | Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| AU2017306557B2 (en) | 2016-08-03 | 2023-08-03 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| CN111727241B (zh) * | 2017-10-11 | 2025-01-28 | 吴云涛 | 基于cd2信号通路的hiv感染阻断组合及方法 |
| BR112020010816A2 (pt) * | 2017-11-29 | 2020-11-10 | Magenta Therapeutics, Inc. | composições e métodos para a depleção de células de cd2+ |
| CN119857155A (zh) | 2017-11-29 | 2025-04-22 | 海德堡医药研究有限责任公司 | 用于耗尽cd5+细胞的组合物和方法 |
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| WO2021013215A1 (zh) * | 2019-07-23 | 2021-01-28 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗lag-3双特异抗体及其制备方法和应用 |
| EP4126241A1 (de) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispezifische kombinationstherapie zur behandlung proliferativer erkrankungen und autoimmunerkrankungen |
| EP4240491A1 (de) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19-bindende moleküle und verwendungen davon |
| AU2021374083A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2025064885A1 (en) | 2023-09-20 | 2025-03-27 | Evolveimmune Therapeutics, Inc. | Multispecific antibodies that bind cd3 and cd2 and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) * | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| EP0463157A4 (en) * | 1990-01-24 | 1992-06-03 | Biogen, Inc. | Lfa-3 as a vaccine adjuvant |
| US5891841A (en) * | 1991-06-11 | 1999-04-06 | The Center For Blood Research, Inc. | Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof |
| AU677772B2 (en) * | 1991-10-07 | 1997-05-08 | Biogen Idec Ma Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA -3 interaction |
-
1993
- 1993-05-25 US US08/068,946 patent/US5795572A/en not_active Expired - Lifetime
-
1994
- 1994-05-24 CA CA002124126A patent/CA2124126C/en not_active Expired - Lifetime
- 1994-05-25 DE DE69434499T patent/DE69434499T2/de not_active Expired - Lifetime
- 1994-05-25 ES ES94108104T patent/ES2249759T3/es not_active Expired - Lifetime
- 1994-05-25 DK DK94108104T patent/DK0626447T3/da active
- 1994-05-25 AT AT94108104T patent/ATE305971T1/de active
- 1994-05-25 JP JP11116094A patent/JP3863196B2/ja not_active Expired - Lifetime
- 1994-05-25 EP EP94108104A patent/EP0626447B1/de not_active Expired - Lifetime
-
1995
- 1995-05-31 US US08/443,888 patent/US6384198B1/en not_active Expired - Lifetime
- 1995-05-31 US US08/456,221 patent/US5807734A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5807734A (en) | 1998-09-15 |
| DE69434499D1 (de) | 2006-02-16 |
| EP0626447A1 (de) | 1994-11-30 |
| JPH07147983A (ja) | 1995-06-13 |
| ES2249759T3 (es) | 2006-04-01 |
| DE69434499T2 (de) | 2006-06-22 |
| CA2124126C (en) | 2007-10-16 |
| JP3863196B2 (ja) | 2006-12-27 |
| CA2124126A1 (en) | 1994-11-26 |
| US6384198B1 (en) | 2002-05-07 |
| EP0626447B1 (de) | 2005-10-05 |
| DK0626447T3 (da) | 2006-02-20 |
| US5795572A (en) | 1998-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434499D1 (de) | Monoklonale Antikörper und Fv gegen das CD2 Antigen | |
| AU2349697A (en) | Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| AU2936395A (en) | Reconstituted human antibody against human interleukin-8 | |
| DE122004000036I1 (de) | Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma. | |
| PT712863E (pt) | Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica | |
| MC2308A1 (fr) | Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine | |
| NO943653L (no) | Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon | |
| AU2456888A (en) | Monoclonal antibodies specific for HIV and hybridomas for their production | |
| ATE230418T1 (de) | Monoklonaler antikörper gegen das humane mx- protein mxa | |
| PT1042492E (pt) | Anticorpos monoclonais humanizados que protegem contra doença induzida pela toxina shiga | |
| ATE77243T1 (de) | E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom. | |
| ATE62253T1 (de) | Menschlicher, monoklonaler antikoerper und seine herstellung. | |
| JPS6461499A (en) | Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof | |
| DE69435142D1 (de) | Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen | |
| EP0338395A3 (en) | Monoclonal antibodies to pseudomonas aeruginosa, their production and use | |
| KR890700133A (ko) | 인체단일클론항체 및 그것을 활성성분으로 함유하는 감염증의 예방 및 치료제 | |
| DE59207362D1 (de) | Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
| EP0554670A3 (en) | Specific antibodies against activated platelets, their production and applications in diagnostics and therapeutics | |
| DE69010897D1 (de) | Verwendung von monoklonalen Antikörpern gegen B2-Mikroglobulin. | |
| TW223019B (de) | ||
| EP0450573A3 (de) | Antikörper für die Behandlung und die Diagnose von Pseudomonas aeruginosa Infektionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0626447 Country of ref document: EP |